ArticlePLoS neglected tropical diseases2026
Plasmodium knowlesi tryptophan-rich antigen 40.1 binds human erythrocyte spectrin alpha.
Article in PLoS neglected tropical diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Plasmodium infection induces extensive remodeling of host erythrocytes through parasite-exported proteins that interact with host cell components. Among these, tryptophan-rich antigens (TRAgs) are conserved across Plasmodium species and have been proposed as vaccine candidates, but their molecular functions remain largely unexplored. In this study, we characterized Plasmodium knowlesi tryptophan-rich antigen 40.1 (PkTRAg40.1) to investigate its localization, biochemical properties, host interactions, and immunogenicity. Recombinant PkTRAg40.1 showed no detectable binding to intact human erythrocytes in flow cytometry-based binding assays. Biochemical characterization demonstrated that native PkTRAg40.1 was predominantly associated with detergent-resistant insoluble fractions and was detected as multiple higher-molecular-weight forms. Protease protection assays further showed that native PkTRAg40.1 was accessible to protease under the experimental conditions tested. Consistent with these observations, immunofluorescence assays revealed that PkTRAg40.1 colocalized with skeleton-binding protein 1 (PkSBP1), supporting its localization to Sinton and Mulligan's clefts (SMCs), parasite-derived membranous structures. Pull-down assays and MALDI-TOF/MS identified spectrin alpha as a host binding partner, and biolayer interferometry confirmed its specific interaction with the spectrin alpha α12-16 fragment (KD = 4.71 ± 0.62 μM). Serological analysis of P. knowlesi patient samples revealed that PkTRAg40.1 is immunogenic, exhibiting 50% sensitivity and 92.9% specificity, and also displayed cross-reactivity with sera from Plasmodium vivax-infected patients. Collectively, these findings identify PkTRAg40.1 as a TRAg associated with parasite-derived membranous structures that interacts with the host erythrocyte cytoskeleton, thereby expanding current understanding of the molecular functions of Plasmodium TRAgs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.